NICE Begins Construction of RWE Framework, Turns to Aetion for Guidance in Recent Collaboration

The National Institute for Health and Care Excellence (NICE) has begun working on new guidelines that will inform pharmaceutical companies when and how real world evidence (RWE) studies should be submitted. NICE has sought intelligence from Aetion as the two organizations announced a new partnership last week.

“NICE, the health technology appraisal institute for England and Wales, is embarking on work to better understand how real-world evidence (RWE) studies can help fill evidence gaps and reduce uncertainties when the institute is developing guidance on drugs and other health care products. To support these efforts, this week NICE announced a new collaboration with Aetion to determine when and how RWE can support the agency’s decision-making.” Read more here.

(Source: Francesca Bruce, Pink Sheet, 10/7/21)